Soleno Therapeutics to Participate in Upcoming November Conferences

Core Insights - Soleno Therapeutics, Inc. is participating in multiple investor conferences in November 2025, showcasing its commitment to engaging with the investment community [1] - The company focuses on developing novel therapeutics for rare diseases, with its first commercial product being VYKAT XR™, an oral treatment for hyperphagia associated with Prader-Willi syndrome [2] Group 1: Upcoming Investor Conferences - Soleno will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2025, at 9:00 AM ET in a fireside chat format [1] - The company will also participate in the Stifel 2025 Healthcare Conference on November 12, 2025, at 8:40 AM ET, again in a fireside chat format [1] - Additionally, Soleno is scheduled to present at the Jefferies London Healthcare Conference on November 18, 2025, at 5:00 PM GMT [1] Group 2: Company Overview - Soleno Therapeutics is dedicated to the development and commercialization of therapeutics aimed at treating rare diseases [2] - The company's first product, VYKAT XR™ (diazoxide choline) extended-release tablets, is designed for once-daily oral administration for patients aged 4 years and older with Prader-Willi syndrome [2]